AI Science Tracker
EN

Ovarian Recurrence risk Assessment using Clinical and serum protein LEvels (ORACLE): A Machine Learning Risk Score to Predict Survival in High Grade Ovarian Cancer

Affiliation not stated in the reviewed material · 25 Jul 2023 · medicine

Discovery

Ovarian Recurrence risk Assessment using Clinical and serum protein LEvels (ORACLE): A Machine Learning Risk Score to Predict Survival in High Grade Ovarian Cancer

Source check: Source checked. Not independent scientific confirmation.

Finding: The ORACLE ML risk score combines serum proteins and clinical factors to predict ovarian-cancer recurrence and is evaluated in an independent prospectively collected cohort; the abstract supports a disease-specific prognostic result.

Technology: The ORACLE machine-learning risk score combines serum-protein and clinical predictors to estimate ovarian-cancer recurrence and survival.

Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The ORACLE machine-learning risk score combines serum-protein and clinical predictors to estimate ovarian-cancer recurrence and survival.
Test and result
The preprint reports evaluation in an independent prospectively collected cohort for disease-specific recurrence/survival prediction.
Limitation / still unknown
The preprint and described cohort evidence do not establish clinical utility; external reproducibility and prospective impact are unknown.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.researchsquare.com/article/rs-3112324/v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.